RANI240719P2500
- 0.05
- 0.000.00%
Rani Therapeutics Newsroom
Express News | Rani Therapeutics-After Evaluating Ongoing Business Development,Business Outlook,Elected Not to Move Forward With Equity Financing at This Time
Express News | Rani Therapeutics Holdings - After Evaluating Cash Position, Business, Elected Not to Move Forward With Equity Financing at This Time
Express News | Rani Therapeutics Holdings Inc - Had Recently Engaged in Discussions With Various Investors to Explore a Potential Equity Financing.
Maxim Group Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $15
Maxim Group analyst Michael Okunewitch maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 26.
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $13
H.C. Wainwright analyst Mitchell Kapoor maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 32
BTIG Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $14
BTIG analyst Julian Harrison maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 47.0% and a t
Express News | Rani Therapeutics: Co, Progen to Share Responsibilities for Rt-114, Including 50/50 Cost & Revenue Share
Express News | Rani & Progen Partnership With No Upfront Payment
Express News | Rani Therapeutics & Progen Co-Develop Rt-114
Rani Therapeutics Has Entered Into A Definitive Agreement With ProGen For The Co-development And Commercialization Of RT-114, An Oral Ranipill Capsule Containing ProGen's PG-102, A GLP-1/GLP-2 Dual Agonist, For Obesity
Under the terms of the collaboration agreement, Rani and ProGen agree to share responsibilities for the development and commercialization of RT-114 worldwide, including a 50/50 cost and revenue share
Express News | Rani Therapeutics Announces Partnership With Progen on Development of Oral Obesity Treatment
Maxim Group Initiates Rani Therapeutics(RANI.US) With Buy Rating, Announces Target Price $15
Maxim Group analyst Michael Okunewitch initiates coverage on $Rani Therapeutics(RANI.US)$ with a buy rating, and sets the target price at $15.According to TipRanks data, the analyst has a success rate
Express News | Rani Therapeutics Holdings Inc : Maxim Group Initiates Coverage With Buy Rating; Target Price $15
Rani Therapeutics Initiated at Buy by Rodman & Renshaw
Rani Therapeutics Initiated at Buy by Rodman & Renshaw
Express News | Rodman & Renshaw Initiates Coverage On Rani Therapeutics Hldgs With Buy Rating, Announces Price Target of $10
Rodman & Renshaw Initiates Rani Therapeutics(RANI.US) With Buy Rating, Announces Target Price $10
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Rani Therapeutics(RANI.US)$ with a buy rating, and sets the target price at $10.According to TipRanks data, the analyst has a success rate
Express News | Rani Therapeutics Holdings Inc : UBS Raises Target Price to $8 From $4
Rani Therapeutics to Participate in May Investor Conferences
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Express News | BTIG Maintains Buy on Rani Therapeutics Hldgs, Raises Price Target to $14